The Year in Medicine 2008
In good times and bad, science doesn't sleep, and every year brings breakthroughs, setbacks, reasons for worry and reasons for joy. TIME's annual alphabetical roundup of a sampling of those stories gives you an overview of the year behind and a hint of what might be in the one ahead.
Vytorin: Science Vs. Hype
If one cholesterol-lowering drug is good, two must be better. That was the thinking behind Vytorin, a combination of Merck's Zocor and Schering-Plough's Zetia. Not so, it turns out. A study of 750 patients showed that while the combination did lower bad cholesterol, or LDL, it did little more to reduce the dangerous buildup of plaque than Zocor alone did — which costs far less than the combination drug Vytorin.
View the full list for "The Year in Medicine 2008"Special Features:
Most Popular »
- The '00s: Goodbye (at Last) to the Decade From Hell
- The Growing Backlash Against Overparenting
- Black Friday Sales Were Encouraging, Retailers Say
- How to Get Smarter, One Breath at a Time
- Will Dubai's Financial Problems Spread Around the Globe?
- Obama's 'Mistakes': Way Too Early to Judge
- Germany's Doubts About Afghanistan Grow After Revelations About Air Strike
- Behind the Philippines' Maguindanao Massacre
- In Italy, A Sex Scandal to Rival Berlusconi's
- A Brief History Of Black Friday
- The '00s: Goodbye (at Last) to the Decade From Hell
- The Growing Backlash Against Overparenting
- How to Get Smarter, One Breath at a Time
- Is Gene Therapy Finally Ready for Prime Time?
- Obama's 'Mistakes': Way Too Early to Judge
- Iran Seizes Nobel Peace Medal
- The Gospel of Glee: Is It Anti-Christian?
- Hidden College Costs: Rising Fees
- How Silvio Berlusconi Uses Women on TV
- Nation: LINCOLN AND MODERN AMERICA
RSS